Windtree Therapeutics, Inc. Cost of Revenue

Cost of Revenue of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending March 30, 2015 was $929 Thousand (a 2.99% increase compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue increased by 27.09%
  • Annual Cost of Revenue for 2015 was $929 Thousand (a -65.22% decrease from previous year)
  • Annual Cost of Revenue for 2014 was $2.67 Million (a 416.63% increase from previous year)
  • Twelve month Cost of Revenue ending March 30, 2015 was $2.82 Million (a 5.54% increase compared to previous quarter)
Trailing Cost of Revenue for the last four month:
30 Mar '15 30 Dec '14
$2.82 Million $2.67 Million
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of Windtree Therapeutics, Inc.

Most recent Cost of Revenueof WINT including historical data for past 10 years.

Interactive Chart of Cost of Revenue of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2015 $0.93 $0.93
2014 $0.9 $0.26 $0.73 $0.78 $2.67
2013 $0.52

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.